Leucopenia during sulphasalazine treatment for rheumatoid arthritis.
AUTOR(ES)
Marabani, M
RESUMO
Leucopenia appears to be a more frequent complication of sulphasalazine treatment in rheumatoid arthritis than in inflammatory bowel disease and poses a management problem. In this study leucopenia was found in 20 patients, 14 of whom were participating in prospective studies (252 patients), giving an incidence of 5.6%. Treatment had to be discontinued in half of these patients. Most (14) episodes of leucopenia occurred early in treatment (less than 24 weeks) but some occurred late and sustained monitoring seems necessary. No predictive factors for leucopenia were elucidated. All patients recovered fully with dose adjustment or, in more severe cases, after withdrawal of sulphasalazine and appropriate supportive therapy. The incidence of leucopenia may be higher in Glasgow than in other units in Britain.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1003796Documentos Relacionados
- Sulphasalazine treatment in rheumatoid arthritis.
- HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.
- Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.
- Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.
- Leucopenia after gold and sulphasalazine treatment.
